Clinical trial
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
NCT00029107 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00029107 |
|---|---|
| Title | Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis |
| Official title | Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Vasculitis |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 47 |
| Start date | Dec 1, 2001 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Jan 7, 2002 |
| Last update posted | Apr 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: